Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma.

Autor: Fernández-Galván A; Dermatology Department, Hospital Universitario La Princesa, Diego de León St. 62, 28006 Madrid, Spain., Rodríguez-Jiménez P; Dermatology Department, Hospital Universitario La Princesa, Diego de León St. 62, 28006 Madrid, Spain.; Dermatology Department, Hospital Ruber Internacional, 28034 Madrid, Spain., González-Sixto B; DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Pontevedra, Spain., Abalde-Pintos MT; DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36213 Pontevedra, Spain., Butrón-Bris B; Dermatology Department, Hospital Universitario La Princesa, Diego de León St. 62, 28006 Madrid, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Jun 04; Vol. 16 (11). Date of Electronic Publication: 2024 Jun 04.
DOI: 10.3390/cancers16112135
Abstrakt: Basal Cell Carcinoma (BCC) is the most common type of cancer among the white population. Individuals with fair skin have an average lifetime risk of around 30% for developing BCC, and there is a noticeable upward trend in its incidence rate. The principal treatment objectives for BCC involve achieving the total excision of the tumor while maximizing the preservation of function and cosmesis. Surgery is considered the treatment of choice for BCC for two main reasons: it allows for the highest cure rates and facilitates histological control of resection margins. However, in the subgroup of patients with low-risk recurrence or medical contraindications for surgery, new non-surgical treatment alternatives can provide an excellent oncological and cosmetic outcome. An evident and justified instance of these local therapies occurred during the COVID-19 pandemic, a period when surgical interventions carried out in hospital settings were not a viable option.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje